BACKGROUND:PPAR-gamma agonists improve insulin sensitivity and glycemic control in type 2 diabetes and may reduce atherosclerosis progression. Thus, PPAR-gamma agonists may be an effective therapy for metabolic syndrome. However, the full spectrum of potentially antiatherogenic mechanisms of PPAR-gamma agonists have not been fully tested in nondiabetic patients with metabolic syndrome. METHODS AND RESULTS: We performed a prospective, double-blinded, placebo-controlled study of 60 nondiabetic subjects with low high-density lipoprotein cholesterol (HDL-C) level and metabolic syndrome torosiglitazone 8 mg daily or placebofor 12 weeks. We found no significant effect of rosiglitazone on HDL-C (+5.5% versus +5.8%, P=0.89), and an increase in total cholesterol (+8% versus -1%; P=0.03). Nevertheless, rosiglitazone significantly increased adiponectin (+168% versus +25%; P<0.001), and lowered resistin (-6% versus +4%; P=0.009), C-reactive protein (-32% versus +36%, P=0.002), interleukin (IL)-6 (-22% versus +4%, P<0.001), and soluble tumor-necrosis factor-alpha receptor-2 (-5% versus +7%, P<0.001). CONCLUSIONS: These findings suggest that rosiglitazone, presumably through its PPAR-gamma agonist properties, has direct effects on inflammatory markers and adipokines in the absence of favorable lipid effects. These findings may help explain the mechanism underlying the possible antiatherosclerotic effects of rosiglitazone.
RCT Entities:
BACKGROUND:PPAR-gamma agonists improve insulin sensitivity and glycemic control in type 2 diabetes and may reduce atherosclerosis progression. Thus, PPAR-gamma agonists may be an effective therapy for metabolic syndrome. However, the full spectrum of potentially antiatherogenic mechanisms of PPAR-gamma agonists have not been fully tested in nondiabeticpatients with metabolic syndrome. METHODS AND RESULTS: We performed a prospective, double-blinded, placebo-controlled study of 60 nondiabetic subjects with low high-density lipoprotein cholesterol (HDL-C) level and metabolic syndrome to rosiglitazone 8 mg daily or placebo for 12 weeks. We found no significant effect of rosiglitazone on HDL-C (+5.5% versus +5.8%, P=0.89), and an increase in total cholesterol (+8% versus -1%; P=0.03). Nevertheless, rosiglitazone significantly increased adiponectin (+168% versus +25%; P<0.001), and lowered resistin (-6% versus +4%; P=0.009), C-reactive protein (-32% versus +36%, P=0.002), interleukin (IL)-6 (-22% versus +4%, P<0.001), and soluble tumor-necrosis factor-alpha receptor-2 (-5% versus +7%, P<0.001). CONCLUSIONS: These findings suggest that rosiglitazone, presumably through its PPAR-gamma agonist properties, has direct effects on inflammatory markers and adipokines in the absence of favorable lipid effects. These findings may help explain the mechanism underlying the possible antiatherosclerotic effects of rosiglitazone.
Authors: John S Millar; Katsunori Ikewaki; LeAnne T Bloedon; Megan L Wolfe; Philippe O Szapary; Daniel J Rader Journal: J Lipid Res Date: 2010-10-22 Impact factor: 5.922
Authors: Ebele C Chira; Timothy S McMillen; Shari Wang; Antonio Haw; Kevin D O'Brien; Thomas N Wight; Alan Chait Journal: Atherosclerosis Date: 2007-01-09 Impact factor: 5.162
Authors: Fernanda M Consolim-Colombo; Carine T Sangaleti; Fernando O Costa; Tercio L Morais; Heno F Lopes; Josiane M Motta; Maria C Irigoyen; Luiz A Bortoloto; Carlos Eduardo Rochitte; Yael Tobi Harris; Sanjaya K Satapathy; Peder S Olofsson; Meredith Akerman; Sangeeta S Chavan; Meggan MacKay; Douglas P Barnaby; Martin L Lesser; Jesse Roth; Kevin J Tracey; Valentin A Pavlov Journal: JCI Insight Date: 2017-07-20
Authors: D C Henderson; X Fan; B Sharma; P M Copeland; C P Borba; R Boxill; O Freudenreich; C Cather; A Eden Evins; D C Goff Journal: Acta Psychiatr Scand Date: 2009-01-12 Impact factor: 6.392
Authors: Dongming Su; Gina M Coudriet; Dae Hyun Kim; Yi Lu; German Perdomo; Shen Qu; Sandra Slusher; Hubert M Tse; Jon Piganelli; Nick Giannoukakis; Jian Zhang; H Henry Dong Journal: Diabetes Date: 2009-08-03 Impact factor: 9.461